Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 24 Jun, 01:30 am
Trip.com Group Ltd. (NASDAQ: TCOM) is set to announce its Q1 2026 earnings on June 24, 2026. Analysts project an earnings per share (EPS) of $0.85 on revenues of approximately $2.30 billion . The company exhibits a trailing Price-to-Earnings (P/E) ratio of 6.21 , a Price-to-Sales
Roth Capital has set a new price target of $2.75 for Outdoor Holding Company (NASDAQ: POWW), indicating a potential upside of 17% . Despite reporting a wider-than-expected quarterly loss of 3 cents per share , Outdoor Holding Company's Q4 sales of $13.89 million surpassed analyst
Earnings Outlook: Analysts anticipate a negative earnings per share (EPS) of -$0.03 and revenues of $2.38 million for Richtech Robotics Inc.'s upcoming report. Financial Health: Despite current unprofitability, Richtech Robotics Inc. demonstrates balance sheet strength with a ver
Apogee Therapeutics (NASDAQ: APGE) is being acquired by AbbVie (NYSE: ABBV) for approximately $10.90 billion , with shareholders set to receive $135.11 per share . Following the acquisition announcement, analysts downgraded Apogee Therapeutics to a "Hold" rating, setting a new pr
Recent insider selling by a DocuSign executive and other insiders totals $3.1 million , with no reported insider buying, potentially signaling internal concerns. DocuSign stock has experienced significant declines, falling 37.8% year-to-date and 43.1% over the past year, with its
Truist Financial has increased its price target for Incyte (NASDAQ: INCY) to $105.00 , indicating a potential 1.73% upside. Incyte secured regulatory approval for its drug Minjuvi® in Japan, expanding its market reach for blood cancer treatments . Positive Phase II results for zi
Apogee Therapeutics, Inc. (NASDAQ:APGE) surged due to an acquisition offer from AbbVie Inc. (NYSE:ABBV) . Definium Therapeutics, Inc. (NASDAQ:DFTX) saw significant gains following its announcement of a $500 million public offering. Several companies saw major stock price increase
Today's market saw significant declines, particularly impacting leveraged exchange-traded funds (ETFs) and the agricultural sector. Sadot Group Inc. (NASDAQ: SDOT) experienced a substantial drop. Leveraged ETFs tracking Direxion Daily SpaceX Bull 2X ETF (NASDAQ: LOFF) , T-REX 2X
Paychex is projected to report robust Q4 earnings, driven by significant revenue and EPS growth. Growth is primarily fueled by the company's management solutions segment and strategic pricing gains, indicating strong financial performance . Investors can note Paychex 's attractiv
Cerebras Systems Inc. (NASDAQ: CBRS): AI-Compute Growth Meets Valuation Debate Cerebras Systems Inc. operates in the fast-growing AI-compute market, where it competes with larger and more diversified semiconductor companies such as Nvidia and AMD. The company has attracted bullis
Outdoor Holding Company (NASDAQ: POWW) Q4 Earnings: Revenue Beat, Narrower Losses, and Cost Discipline Outdoor Holding Company reported quarterly revenue of $13.89 million , beating analyst expectations. The company narrowed its net loss attributable to common shareholders to $1.
Spruce Biosciences (NASDAQ: SPRB) is developing a late-stage therapy (TA-ERT) for Sanfilippo Syndrome Type B , a rare pediatric neurodegenerative disorder with no current FDA-approved treatments . The biopharmaceutical company has appointed Dr. Agnieszka Jurecka as VP of Medical
Investment firm Citigroup maintains a "Neutral" rating for Rivian (NASDAQ: RIVN) with a price target of $15.38 , reflecting current market conditions and its electric vehicle (EV) market outlook. Rivian faces market pressure, including a class-action lawsuit regarding "Level 3 au
Regenxbio Inc. (NASDAQ: RGNX) Surges on Positive Analyst Outlook and FDA Alignment for Gene Therapy Analyst Brian Skorney of Robert W. Baird raised the price target for Regenxbio Inc. to $32.00 , indicating significant upside potential. Regenxbio Inc. has aligned with the FDA for
Apogee Therapeutics (NASDAQ: APGE) is being acquired by AbbVie (NYSE: ABBV) for approximately $10.9 billion , a strategic move aimed at expanding AbbVie's immunology drug portfolio. Analyst firm Craig-Hallum downgraded Apogee Therapeutics stock from a "Buy" to a "Hold" rating, ci
UBS analyst Manav Gupta confirmed a Buy rating for Bloom Energy, setting a price target of $322.00 , reflecting confidence in the company's future. Bloom Energy's solid oxide fuel cell technology is positioned as a critical solution for the escalating electricity demands of artif
CVS Health (NYSE:CVS) is demonstrating strong market momentum, with its stock price nearing its 52-week high, reflecting robust performance. The company is strategically expanding into the GLP-1 medication market, leveraging its extensive network of 9,000 pharmacies and virtual M
Safe Bulkers, Inc. reported robust first-quarter results, significantly surpassing analyst expectations for both earnings per share and revenue. The company demonstrated strong profitability with an official EPS of $0.20 and a net income of $22.20 million . Key financial metrics,
Headlines provided by Investing.com